CMS makes ocular surface anesthesia more accessible

CMS has issued a product-specific code for Harrow’s new ocular surface anesthesia Iheezo, enabling a more efficient billing process for healthcare providers. 

Advertisement

Iheezo, a topical anesthetic approved by the FDA in Sept. 2022, is the first ocular anesthetic approved for use in 14 years, according to a Feb. 2 press release. 

Iheezo does not require patients to receive any supplemental anesthesia to undergo surgical procedures. 

By receiving a product-specific CMS code, ophthalmologists, optometrists and retina specialists will be able to easily bill for Iheezo, creating greater accessibility for the product. 

Advertisement

Next Up in Ophthalmology

  • Nancy Williams-Wallace, MD, is closing her ophthalmology practice, Tampa Bay Eye Associates, located in Palm Harbor, Fla., according to a…

  • Sightview, an electronic health record and practice management partner focused on eyecare, has appointed Tycene Fritcher as CEO.  Ms. Fritcher…

Advertisement

Comments are closed.